| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Institute for Animal Health, Compton Laboratories, Newbury, Berkshire RG20 7NN, UK
2 Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
Correspondence
Louise Kirby
louise.kirby{at}bbsrc.ac.uk
Prion diseases are associated with the conversion of the normal cellular prion protein, PrPC, to the abnormal disease-associated protein, PrPSc. This conversion can be mimicked in vitro using PrPSc isolated from the brains of scrapie-infected animals to induce conversion of recombinant PrPC into a proteinase K-resistant isoform, PrPres. Traditionally, the ‘cell-free’ conversion assay has used, as substrate, recombinant PrPC purified from mammalian tissue culture cells or, more recently, from baculovirus-infected insect cells. The cell-free conversion assay has been modified by replacing the tissue culture-derived PrPC with recombinant PrP purified from bacteria. Bacterial expression and chromatographic purification give high yields of recombinant radiolabelled untagged protein, eliminates artefacts that may be due to cellular factors or antibody fragments normally present in labelled PrP preparations and allows accurate and rapid variation of protein sequence using standard molecular biological techniques. In addition, these cell-free conversion assays were carried out under more physiological conditions, giving more relevance to the assay as a model for conversion. To validate its use in this assay, this bacterial recombinant PrP has been shown to have the conversion properties of mammalian PrPC: (i) it converts to a proteinase K-resistant isoform in the presence of PrPSc; (ii) the efficiency of this conversion by PrPSc of different strains and species parallels that found in vivo; and (iii) its cell-free conversion is inhibited by Congo Red analogues in a structure-dependent manner similar to that seen in in vivo and in vitro cell assays.
Published ahead of print on 24 January 2003 as DOI 10.1099/vir.0.18903-0.
Present address: VLA Lasswade, International Research Centre, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 OPZ, UK.
This article has been cited by other articles:
|
|
 |
|
  N. Makarava, C.-I Lee, V. G. Ostapchenko, and I. V. Baskakov Highly Promiscuous Nature of Prion Polymerization J. Biol. Chem., December 14, 2007; 282(50): 36704 - 36713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Webb, T. Lekishvili, C. Loeschner, S. Sellarajah, F. Prelli, T. Wisniewski, I. H. Gilbert, and D. R. Brown Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds J. Virol., October 1, 2007; 81(19): 10729 - 10741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Spinner, R. B. Kascsak, G. LaFauci, H. C. Meeker, X. Ye, M. J. Flory, J. I. Kim, G. B. Schuller-Levis, W. R. Levis, T. Wisniewski, et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils J. Leukoc. Biol., June 1, 2007; 81(6): 1374 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kirby, W. Goldmann, F. Houston, A. C. Gill, and J. C. Manson A novel, resistance-linked ovine PrP variant and its equivalent mouse variant modulate the in vitro cell-free conversion of rPrP to PrPres J. Gen. Virol., December 1, 2006; 87(12): 3747 - 3751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eiden, G. J. Palm, W. Hinrichs, U. Matthey, R. Zahn, and M. H. Groschup Synergistic and strain-specific effects of bovine spongiform encephalopathy and scrapie prions in the cell-free conversion of recombinant prion protein J. Gen. Virol., December 1, 2006; 87(12): 3753 - 3761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R Trevitt and J. Collinge A systematic review of prion therapeutics in experimental models Brain, September 1, 2006; 129(9): 2241 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. V. Baskakov Autocatalytic Conversion of Recombinant Prion Proteins Displays a Species Barrier J. Biol. Chem., February 27, 2004; 279(9): 7671 - 7677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rhie, L. Kirby, N. Sayer, R. Wellesley, P. Disterer, I. Sylvester, A. Gill, J. Hope, W. James, and A. Tahiri-Alaoui Characterization of 2'-Fluoro-RNA Aptamers That Bind Preferentially to Disease-associated Conformations of Prion Protein and Inhibit Conversion J. Biol. Chem., October 10, 2003; 278(41): 39697 - 39705. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
